http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-817180-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a8fbd6ff8b6c09e0c69a43cda79b557 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 |
| filingDate | 1957-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1959-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-817180-A |
| titleOfInvention | Tetracycline metallo salt complex |
| abstract | The invention relates to a tetracycline metallo-hexametaphosphate complex wherein the metallo - hexametaphosphate is sodium hexametaphosphate or potassium hexametaphosphate. The sodium complex is stable, non-toxic, insoluble substance (3.2 mg./ml. in water at room temperature), containing 0.7 to 1.2 per cent sodium and 5.8 to 7.8 per cent phosphorus on anhydrous basis, a potency of 760 to 940 mcg/ml. tetracycline hydrochloride, and producing at the end of 1 and 4 hours after oral administration to man a concentration in the blood stream substantially greater than that produced by an equivalent amount of tetracycline hydrochloride. It is produced by mixing an aqueous solution containing at least 3 mg/ml. of tetracycline, as the base or as a metal or acid addition salt thereof, and an aqueous solution, containing sodium hexametaphosphate in an amount, by weight of from 1/20 to 2 times that of the tetracycline, the pH of the solutions being below 2.0, e.g. pH 1.5. The precipitate so formed is collected, washed with methanol and dried. The tetracycline sodium hexametaphosphate complex is used medicinally (see Group VI).ALSO:A therapeutic composition comprises a tetracycline sodium hexametaphosphate complex (see Group IV (b)) and one or more solid carriers. It may be a powder, tablet, capsule or suspension in aqueous or oily liquids, e.g. peanut oil, sesame oil or coconut oil having a setting-point below 60 DEG F. Capsules may contain the complex with 5 per cent magnesium stearate and lactose. Tablets are prepared from the complex, calcium mono- and di-basic phosphate, lactose, starch and magnesium stearate. Oral suspensions contain the complex, potassium alginate, sucrose, sodium bisulphite, sodium citrate, saccharin, preservatives and flavours. Optional ingredients are other drugs especially (a) antihistaminics, (b) sulpha drugs, e.g. sulphadiazine, sulphabenzamide, sulphapyridine and benzylsulphanilamide, (c) lipotropic drugs, e.g. methionine, choline, inositol, beta-sitosterol and mixtures thereof, (d) caffeine and amphetamines, (e) local anaesthetics, (f) analgesics such as aspirin, salicylamide, sodium gentisate, p-acetylaminophenol, phenacetin and codeine, (g) laxatives such as phenolphthalein, (h) sedatives such as barbiturates and bromides, (i) antibiotics such as penicillin (l-ephenamine penicillin G, dibenzyl penicillin G and phenoxymethyl penicillin), streptomycin, dihydrostreptomycin, basitracin, polymyxin, tyrothricin, erythromycin, aureomycin, oxytetracycline, oleandomycin, chloramphenicol, "Magnamycin" (Registered Trade Mark), novobiocin and cycloserine, (j) vitamins, e.g. A, A1, B1, B2, B6, B12, folic acid, C, D2, D3 and E, (k) hormones, e.g. cortisone, hydrocortisone, 9a -fluorocortisone, 9a -fluorohydrocortisone, prednisone and prednisolene, (l) anabolic agents, e.g. 11,17-dihydroxy 9a - fluoro - 17a - methyl - 4 - androsten-3-ene and 17a -ethyl-19-nortestosterone, (m) antifungal agents, e.g. mycostatin. |
| priorityDate | 1956-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.